Introduction
Rod bipolar cells (RBCs) are the first excitatory interneurons in the rod visual system. They receive light-dependent synaptic input from rod photoreceptors in the outer plexiform layer (OPL) and contribute to retinal output via AII amacrine cells in the inner plexiform layer (IPL). RBCs are associated with dark-adapted vision (Euler, Haverkamp, Schubert, & Baden, 2014 ), yet recent evidence suggests that RBCs contribute to retinal output under a diverse range of lighting conditions. Under completely dark-adapted conditions, RBCs are sensitive to single-photon responses in rods (Berntson, Smith, & Taylor, 2004; Sampath & Rieke, 2004) . In mesopic conditions, RBCs contribute to the perception of contrast (Abd-El- Barr et al., 2009; Ke et al., 2014) . Finally, in bright light, RBCs may modulate the cone pathway when rods are saturated (Szikra et al., 2014) . The molecular mechanisms required for RBC adaptation to changing luminance conditions are mostly unknown, but compelling evidence implicates the commonlyused RBC marker protein kinase C-alpha (PKCa; Rampino & Nawy, 2011; Ruether et al., 2010; Xiong et al., 2015) .
To gain insight into the mechanisms by which PKCa modulates the RBC light response, we sought to identify RBC proteins that undergo PKCa-dependent phosphorylation. Using a multiplexed tandem mass tag mass spectroscopy-based approach, we previously identified trophoblast glycoprotein (TPBG, also known as 5T4 or WAIF1 [Wnt-activated inhibitory factor 1]) as a novel PKCa-dependent phosphoprotein in RBCs (Wakeham et al., 2019) . TPBG is a type 1 transmembrane glycoprotein with an N-terminal extracellular domain composed of eight leucine rich repeats interspersed by seven N-linked glycosylation sites. The intracellular cytoplasmic domain is capped by a class 1 PDZ-interacting motif (Zhao, Malinauskas, Harlos, & Jones, 2014) and contains two serines which were significantly more likely to be phosphorylated in wild type retinas compared to PKCa knockout (Wakeham et al., 2019) .
TPBG was first identified in trophoblasts (Hole & Stern, 1988) and has been mainly studied in embryonic development and in cancer (Barrow, Ward, Rutter, Ali, & Stern, 2005) , where it is required for cell surface expression of CXCR4, a G-protein coupled receptor that mediates a chemotactic response to the CXCL12 chemokine (McGinn, Marinov, Sawan, & Stern, 2012; Southgate et al., 2010) , and where it is diagnostic for metastasis and poor prognosis in cancer patients (Pukrop & Binder, 2008; Weeraratna et al., 2002) . In mammalian embryonic cell lines, TPBG influences cytoskeletal organization and cell motility through modulation of Wnt signaling (Kagermeier-Schenk et al., 2011) , and has also shown to bind to the PDZ domain of GIPC1, a scaffolding protein that regulates cell surface expression of G protein-coupled receptors (Awan et al., 2002) . In adult tissues, it is expressed at high levels in ovary, brain, and retina (Imamura et al., 2006; King, Sheppard, Westwater, Stern, & Myers, 1999) . Relatively little is known about the role of TPBG in neurons; however, in the olfactory bulb, TPBG has been shown to drive developmental changes in the dendritic morphology of granule cells in an activity-dependent manner, and genetic knockdown of TPBG resulted in impaired odor discrimination Yoshihara et al., 2012; .
In the retina, a comprehensive single-cell drop-seq study identified TPBG as a possible new RBC marker and clustered it with proteins involved in lamination and adhesion (Shekhar et al., 2016) . In a subsequent comparative meta-analysis of RBC transcriptomics studies, it was grouped as a protein potentially involved in synapse assembly (Woods, Mountjoy, Muir, Ross, & Atan, 2018) . As TPBG has never been thoroughly examined in RBCs, we characterized its expression and subcellular localization patterns in both the adult and developing mouse retina.
Methods

Antibody characterization
Rabbit anti-5T4 (TPBG-CT) (1:500 [immunofluorescence], 1:5000 [immunoblot]; Abcam; Cambridge, UK; Cat# ab129058; RRID: AB_11144484) is a monoclonal antibody targeting a 15-amino acid synthetic peptide immunogen corresponding to a sequence within amino acids 385-420 of human TPBG. TPBG immunoreactivity was verified by the manufacturer via immunoblot of rat brain, HeLa cell, and HT-1376 cell lysates, and immunoprecipitation from MCF-7 cell lysates and detected broad bands of glycosylated proteins at 70-80 kDa (manufacturer information).
Sheep anti-5T4 (TPBG-NT) (1:500; R&D Systems; Minneapolis, MN, USA; Cat# AF5049; RRID: AB_2272148) is a polyclonal antibody raised against amino acids 30 to 361 of mouse TPBG. The manufacturer used flow cytometry and immunocytochemistry to detect TPBG in the membranes of retinoic acid-treated D3 mouse cell lines (manufacturer information). We confirmed specificity of both the TPBG-CT and TPBG-NT antibodies by immunoprecipitation followed by immunoblotting from while type mouse retinal lysate and TPBG-transfected HEK293 cells, with both antibodies detecting a broad band around 72 kDa.
Mouse anti-PKCa (1:5000; Sigma-Aldrich; St. Louis, MO, USA; Cat# P5704; RRID: AB_477375) is a monoclonal antibody that recognizes an epitope between amino acids 296-317 on the hinge region of mouse PKCa. The manufacturer detected bands at 80 kDa in immunblots of lysates from SH-SY5Y, SK-N-SH, COS7, and PC12 cell lines (manufacturer information), and we have verified this antibody by immunoblots of retinal lysates from wild type and PKCa-KO mice.
Mouse anti-CANA1S (1:4000; anti-GPR179; Abcam; Cat# ab2862; RRID: AB_2069567) is a monoclonal antibody raised against full-length native rabbit CACNA1S subunit purified from the rabbit muscle T-tubule dihydropyridine receptor. This CACNA1S antibody has been shown to strongly cross-react with retinal GPR179 in the tips of ON-bipolar cell dendrites (Hasan, Ray, & Gregg, 2016) .
Mouse anti-CtBP2 (1:4000; BD Biosciences; San Jose, CA, USA; Cat# 612044; RRID: AB_399431) is a monoclonal antibody that binds an epitope within amino acids 361-445 of mouse CtBP2. The manufacturer used western blot analysis on BC3H1 cell lysates and detected a band at 48 kDa (manufacturer information). This antibody produces strong immunoreactivity in both nuclei and horseshoe-shaped synaptic ribbons in wild type mouse retina sections, as is characteristic of CtBP2 (Schmitz, Königstorfer, & Südhof, 2000) .
Mouse anti-calretinin (1:25; Santa Cruz Biotechnology; Dallas, TX, USA; Cat# sc-365956; RRID: AB_10846469) is a monoclonal antibody that recognizes an epitope between amino acids 2-27 at the N-terminus of human calretinin. The manufacturer used western blot analysis to detect bands between 23 and 34 kDa from human cerebellum, human brain, human adrenal gland, and rat cerebellum lysates (manufacturer information). We confirmed specificity by labeling wild type mouse retina sections and detected the characteristic three-band pattern of calretinin in the IPL. 
Expression vector
The TPBG expression vector contains full-length mouse TPBG cDNA (NM_011627.4) inserted into the pCMV-sport6 plasmid (Thermo Scientific; Cat# 12209) provided by the PlasmID Repository (Clone ID: MmCD00318800; Species ID: 21983; Harvard Medical School; Boston, MA, USA).
Mice
Wild type mice used were C57BL/6J (Jackson Laboratory; Bar Harbor, ME, USA; Cat#000664, RRID: IMSR_JAX:000664). The PKCa knockout mice were B6;129-Pkrca tm1Jmk /J (Jackson Laboratory; Cat# 009068; Xiong et al., 2015) . The TRPM1 knockout mice were Live cells: Cells grown on coverslips were washed with PBS and given fresh DMEM medium. Primary antibody was added directly to the medium, and the cells were placed on ice for 1 hr, after which they were washed with PBS, fixed with 4% PFA, and permeabilized with AIS.
The remaining steps were identical to the previous section.
Tissue preparation for immunofluorescence
Adult mouse retina sections: Mouse eyecups were prepared from freshly dissected eyes by cutting behind the ora serrata and removing the cornea and lens. Developing mouse retina sections: Mouse eyes were freshly dissected and a small cut was made behind the ora serrata to allow fixative and cryoprotectant penetration into the retina.
The whole eye was then fixed for 30 min by immersion in 4% PFA in PBS. The fixed eyes were then cryoprotected via sequential immersion in 10, 20, and 30% sucrose in PBS until they sank.
Immunostaining retina sections
Retina sections were thawed and then blocked and permeabilized by incubation at room temperature for 30-60 min in AIS, and then were incubated in primary antibodies for 1 hr at room temperature. After washing with PBS, the sections were incubated in secondary antibodies diluted in AIS for 1 hr at room temperature. Finally, the sections were incubated for 1 min in 1X DAPI.
The slides were washed again in PBS and then mounted with Lerner Aqua-Mount. For the TPBG-CT antibody, retina sections were post-fixed for 15 min in 4% PFA before the blocking and permeabilization step as this was found to improve the immunofluorescence with this antibody.
Scanning confocal imaging
Immunofluorescence images were taken with a Leica TCS SP8 X white light laser confocal microscope (Leica; Wetzlar, Germany) using a Leica HC PL APO CS2 63x/1.40 oil immersion objective (Leica; Cat# 15506350) and Leica HyD hybrid detectors. Laser lines used were DAPI (405 nm), AF488 (499 nm), Cy3 (554 nm), and AF594 (598 nm). Detection windows used were DAPI (415-489nm), AF488 (509-544nm), Cy3 (564-758 nm), and AF594 (608-766nm). Zprojections intended for comparison were processed in LAS X using identical tissue thicknesses and a "Threshold" setting of 20. Brightness and contrast were adjusted equally across comparison groups using Leica LAS X or ImageJ (Rueden et al., 2017) . The ImageJ "Smooth" tool was used to remove graininess from images. Figure 3C was deconvolved with the Huygens HyVolution 2 module (Scientific Volume Imaging; The Netherlands) with the "standard" algorithm and a refractive index of 1.454.
Immunoblotting
Retinas were extracted from freshly dissected eyes, suspended in chilled lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% deoxycholate, 0.1% SDS) with 1X protease/phosphatase inhibitor cocktail (Cell Signaling Technology; Danvers, MA, USA; Cat# 5872) and homogenized with a Teflon-glass homogenizer. The lysate was centrifuged for 15 min at 16,400 rpm and 4° C, and the pellet was discarded. Lysates were stored at -20° C. Retinal lysates were diluted to 1µg/µl in lysis buffer and brought to 1X NuPAGE LDS Sample Buffer (Thermo Scientific; Cat# NP0007) and 1X NuPAGE Sample Reducing Agent (Thermo Scientific; Cat# NP0009). Pre-cast NuPAGE 1mm 4-12% Bis-Tris gels (Thermo Scientific; Cat# NP0322BOX) were loaded and run at 200 V and 140 mA for 55 min in 1X NuPAGE BOLT SDS Running Buffer (Thermo Scientific; Cat# B0001). Proteins were transferred onto PVDF membranes using a semi-dry transfer system and 2X NuPAGE Transfer Buffer (Thermo Scientific; Cat# NP00061) with 10% MeOH at 45 mA for 2 hrs, or a wet transfer system and 1X NuPAGE
Transfer Buffer with 5% MeOH at 300mA for 2 hrs. The membranes were then rinsed with methanol and blocked for 1 hr in Odyssey Blocking Buffer TBS (LI-COR Biosciences; Cat# 927-50003) on a shaker at room temperature, before being incubated in primary antibody diluted in Odyssey buffer at 4° C overnight. The membranes were washed 3x5 min in TBST (Tris-buffered saline with 0.1% Tween-20), then incubated in secondary antibody diluted in Odyssey buffer for 1 hr at room temperature before being washed 3x5 min in TBST and left to dry. The dry blots were imaged using a LI-COR Odyssey CLx Imaging System at 700 and 800 nm.
Results
TPBG is expressed in the dendrites and synaptic terminals of rod bipolar cells.
Two commercial antibodies against different epitopes of TPBG were purchased. The first, a rabbit monoclonal (TPBG-CT), reacts with an epitope near the PDZ-interacting motif of TPBG's intracellular C-terminal tail, while the second, a sheep polyclonal (TPBG-NT), binds within the extracellular N-terminal leucine-rich repeat (LRR) domain of TPBG.
Wild type adult mouse retina sections were labeled with either anti-TPBG-CT or anti-TPBG-NT, and the nuclear stain DAPI was used to identify the different retinal layers.
Immunofluorescent labeling with anti-TPBG-CT ( Figure 1A ) reveals strong immunoreactivity in the OPL and in two bands in the IPL, one in the middle of the IPL at sublamina 2/3 and the other at the innermost IPL in sublamina 5. In the inner nuclear layer, anti-TPBG-CT labels putative RBC cell bodies as well as a sparse population of amacrine cell bodies. In a dissociated cell preparation Immunofluorescent labeling with anti-TPBG-NT ( Figure 2C and D) reveals punctate immunoreactivity in the OPL and widespread punctate labeling in the IPL that is not confined to sublamina 5. The TPBG-positive amacrine cell bodies and dendrites seen in Figure 1 and 2B are occasionally seen. In the OPL, there is much sparser but more punctate immunoreactivity ( Figure   2C ) than with anti-TPBG-CT. There is less overlap between anti-TPBG-NT and anti-PKCa, particularly in the RBC dendritic tips, which exhibit the strongest TPBG-NT labeling but are only weakly labeled for PKCa. In the IPL, there is punctate labeling across the entire width of the synaptic layer ( Figure 2D ), yet RBC synaptic terminals are still prominent, and all PKCa-positive RBC terminals are also labeled by anti-TPBG-NT.
TPBG is localized to the plasma membrane and cytoplasmic compartments in transfected HEK293 cells.
Based on its structure and similarities with other LRR proteins, TPBG is expected to be oriented in the plasma membrane with its N-terminal LRRs facing the extracellular space and its C-terminal tail in the cytoplasm. Since immunofluorescence in retina sections could not clearly reveal the subcellular distribution of TPBG in RBCs, and to better visualize its distribution within mammalian cells, HEK293 cells were transfected with full-length mouse TPBG and labeled with either the C-terminal or N-terminal TPBG antibodies (Figure 3) . In fixed and permeabilized cells, both antibodies labeled cytoplasmic structures ( Figure 3A ). To prevent intracellular access, the antibodies were also added directly to live transfected cells ( Figure 3B ). Anti-TPBG-CT shows no immunoreactivity in the live cells, confirming the intracellular localization of the C-terminus. Anti-TPBG-NT, on the other hand, labeled the extracellular surface of live transfected HEK293 cells, confirming the predicted orientation of TPBG with the N-terminal, LRR domain facing out.
Additionally, both antibodies labeled thin filopodia-like membrane projections (arrows in Figure   3B ). Deconvolution of a Z-projection of anti-TPBG-CT immunofluorescence in a TPBGtransfected HEK293 cell ( Figure 3C ) revealed thin filopodia-like projections, suggesting plasma membrane localization of TPBG, and bright clusters of immunofluorescence that appear to be localized to the very tips of the projections (arrows in Figure 3C ).
TPBG is present in distal RBC dendrites in the OPL
To examine the dendritic distribution of TPBG in the mouse OPL, we compared TPBG-CT or TPBG-NT immunoreactivity with that of GPR179 and CtBP2 (Figure 4 ). GPR179 is localized exclusively to the dendritic tips of ON-bipolar cells, where it is responsible for anchoring the RGS7-Gb5 complex to the postsynaptic membrane (Orhan et al., 2013; Orlandi, Cao, & Martemyanov, 2013; Tayou et al., 2016) in proximity to mGluR6 (Morgans et al., 2007; Ray et al., 2014) . TPBG-CT-labeled puncta do not completely overlap GPR179 puncta at the very tips of the RBC dendrites, but do closely associate with them (3C, arrows). TPBG-NT puncta, on the other hand, strongly co-localize with GPR179 puncta in the OPL (3D, arrows). In the OPL, antibodies against CtBP2 label ribeye, a protein component of horseshoe-shaped synaptic ribbon structures in both cone and rod photoreceptor synaptic terminals (Schmitz et al., 2000) . Proteins that localize to the tips of RBC dendrites can be visualized as puncta within the concavity of the ribeye horseshoe shape (Morgans et al., 2007) . Both TPBG antibodies reveal punctate immunoreactivity within a subset of CtBP2-positive synaptic terminals ( Figures 3E and F, arrows) , consistent with the presence of TPBG near the tips of RBC dendrites.
TPBG-positive amacrine cells
The IPL is typically divided into two layers corresponding to whether it receives input from ON or OFF bipolar cells, and can be further subdivided into five sublamina (2 OFF sublamina and 3 ON sublamina) based on labeling with immunofluorescence markers. One such IPL marker, calretinin, labels three distinct synaptic layers in the IPL corresponding the sublamina 1/2, 2/3, and 3/4 boundaries (Haverkamp & Wässle, 2000) . 
TPBG immunofluorescence is altered under dark-adapted and knockout conditions
We looked for changes in TPBG expression in dark-adapted, PKCa knockout, and TRPM1 knockout retinas by immunofluorescent labeling and by immunoblotting retinal lysates. For the immunoblot analysis, bands at around 70 kDa corresponding to TPBG were normalized to b-actin bands within each sample to control for changes in total protein between samples. Dark-adaption resulted in a significant reduction in TPBG-CT immunoreactivity in both the OPL and the IPL, including the amacrine cell dendritic layer ( Figure 6A ), though surprisingly, no differences in TPBG levels were seen by immunoblot analysis of lysates from light-adapted and dark-adapted retinas ( Figure 6B ; light-adapted: 1.491, dark-adapted: 1.852, t-test p-value: 0.121, n=3 for both groups).
PKCa knockout resulted in a slight reduction of TPBG-CT immunoreactivity in the OPL and in RBC terminals in the IPL, while the amacrine cell dendritic labeling was unchanged ( Figure 6C ).
Total TPBG expression was unchanged between wild type and PKCa knockout retinal lysates when measured via immunoblot ( Figure 6D ; WT: 0.715, PKCa KO: 0.664, t-test p-value: 0.396, n=3 for both groups). In TRPM1 knockout retina, TPBG-CT immunoreactivity in RBCs was practically abolished when compared to wild type, but the amacrine cell labeling was unaffected ( Figure 6E ). Once again, there was no difference in total TPBG expression between wild type and knockout retina lysates as measured by immunoblot analysis( Figure 6F ; WT: 0.698, TRPM1 KO: 0.748, t-test p-value: 0.710, n=3 for both groups). In contrast to TPBG-CT immunofluorescence, NT immunofluorescence and immunoblots were unchanged by any of the assessed conditions (not shown).
TPBG expression in the retina increases around eye opening.
To analyze the time-course of TPBG expression in the developing mouse retina, retinal lysates were extracted at different postnatal (P) time-points and probed via immunoblot with antibodies to TRPM1 and either TPBG-CT or TPBG-NT ( Figure 7A ). Both TPBG antibodies detect a significant increase in retinal TPBG expression around eye opening, which occurred between P12 and P13, and is concomitant with an increase in the expression of TRPM1. The increase in TPBG expression around eye opening was also apparent in sections made from postnatal mouse retinas labeled with both TPBG antibodies. TPBG immunofluorescence was undetectable in the P0 retina (not shown). In the P6 retina, the TPBG-positive amacrine cell bodies and dendritic projections are just visible when labeled against TPBG-CT ( Figure 7B , left, arrows). By P11, TPBG can be faintly seen in dendritic structures in the OPL ( Figure 7C , arrows), but is still absent from RBC synaptic terminals in the IPL. At P12 ( Figure 7D ), TPBG immunofluorescence in the OPL has drastically increased, as has amacrine cell and RBC synaptic terminal labeling in the IPL. By P13 ( Figure 7E ), after eye opening, RBC dendrites in the OPL are clearly visible when labeled by TPBG-CT, while anti-TPBG-NT puncta have brightened significantly.
Discussion
In this study, we have described the localization and expression patterns of TPBG in the mouse retina using two antibodies against intracellular and extracellular epitopes of TPBG. We found TPBG immunofluorescence primarily in the dendrites and synaptic terminals of RBCs and in the cell bodies and dendritic projections of an uncharacterized class of amacrine cell that stratifies in the middle of the IPL (Figures 1 and 2) . In HEK293 cells, transfected TPBG was primarily localized to the cell membrane and in the tips of membrane projections (Figure 3 ). In the OPL, antibodies against both C-terminal and N-terminal epitopes label puncta closely associated with the tips of the RBC dendrites (Figure 4 ), co-localizing with or near GPR179 and CtBP2. In the IPL, both antibodies against TPBG label the membrane and cytoplasm of RBC synaptic terminals, overlapping with PKCa. Additionally, TPBG-NT appears to label the synaptic terminals of other cell types in the IPL, suggesting possible cross-reactivity with other leucine-rich repeatcontaining proteins.
The N-terminal extracellular region of TPBG contains a heavily glycosylated leucine-rich repeat domain, a common site of protein-protein interactions (Zhao et al., 2014) and several similarly structured transmembrane proteins have recently been identified as vital for the development of the rod-RBC synapse or for localization of RBC synaptic transduction components. ELFN1, a synaptic adhesion LRR protein expressed in rod photoreceptors, forms trans-synaptic complexes with mGluR6 in RBC dendrites, and is required for the development of a functional synapse (Yan Cao et al., 2015; Dunn, Patil, Cao, Orlandi, & Martemyanov, 2018) .
Two other synaptic LRR proteins, LRIT3 and nyctalopin, are required for the localization of TRPM1 to the tips of ON bipolar cell synapses (Y Cao et al., 2011; Neuillé et al., 2017 Neuillé et al., , 2015 Pearring et al., 2011) . Our immunofluorescence data shows that TPBG is localized in distal RBC dendrites and in the RBC synaptic terminals, suggesting a possible role in the development or maintenance of the rod-RBC and RBC-AII synapses. LRR proteins in the IPL that could give rise to cross-reactivity with TPBG-NT include LRIT1 (Ueno et al., 2018) , nyctalopin (Morgans, Ren, & Akileswaran, 2006) , and synaptic adhesion proteins such as FLRTs (Visser et al., 2015) , and neuroligins (M. Hoon et al., 2011; Mrinalini Hoon, Krishnamoorthy, Gollisch, Falkenburger, & Varoqueaux, 2017) .
Immunofluorescent labeling with the C-terminal TPBG antibody was markedly affected by the activity state of the RBCs, with reduced immunofluorescence in dark-adapted, PKCa knockout, and TRPM1 knockout retinas ( Figure 6 ). In contrast, N-terminal immunofluorescence was unaffected, and the total amount of TPBG detected on immunoblots with both TPBG antibodies was unchanged. It is possible that the variations in immunofluorescence observed with anti-TPBG-CT are due to differences in accessibility of the C-terminal epitope. The C-terminal intracellular region of TPBG is capped with a class 1 PDZ-interacting motif containing two serines (S422 and S424) that we have shown to be targets of PKCa-dependent phosphorylation (Wakeham et al., 2019) . Phosphorylation of PDZ-interacting motifs has been shown to regulate binding to PDZ domains. For example, the C-terminal PDZ-interacting motifs of NMDA receptor subunits NR2A and NR2B, end with the amino acids SDV, like TPBG, and phosphorylation of the serine blocks binding of the receptor to the PDZ domain of PSD95 (Chung, Huang, Lau, & Huganir, 2004) . It is not known what PDZ domain proteins may interact with the C-terminal, PDZinteracting motif of TPBG in the retina; however, it has been demonstrated by yeast two-hybrid screening to bind to the PDZ domain of GIPC1, a scaffolding protein that regulates cell surface expression of GPCRs (Awan et al., 2002) that is expressed in RBCs (Shekhar et al., 2016) .
Together, our immunofluorescence and immunoblot results suggest that under conditions where TPBG-CT immunofluorescence is reduced (i.e. dark-adapted conditions, PKCa knockout and TRPM1 knockout), the C-terminus of TPBG may be bound to another protein, possibly containing a PDZ domain, rendering the C-terminal epitope inaccessible to anti-TPBG-CT. Phosphorylation of PDZ-interacting motifs typically abolishes binding to PDZ domains (Chung et al., 2004; Lee & Zheng, 2010) , thus phosphorylation of the TPBG C-terminal serine residues in light-adapted, active RBCs may prevent binding of the interacting protein, permitting antibody binding to the Cterminal epitope.
In the developing mouse retina, TPBG expression is undetectable at birth. The presence of TPBG in amacrine cells is visible by P6, whereas RBC expression increases dramatically just prior to eye opening at P11-P12 ( Figure 6 ). This pattern of increased expression approaching eye opening matches that of TRPM1, and is coincident with the gene expression patterns of many other proteins associated with the final stages of development of signal transduction machinery and establishment of bipolar cell morphology (Blackshaw et al., 2004; Dorrell, Aguilar, Weber, & Friedlander, 2004; Mu et al., 2001; Zhang, Kolodkin, Wong, & James, 2017) . In embryonic development, TPBG alters Wnt and cytokine signaling to modulate cytoskeletal rearrangement and cell morphology (Kagermeier-Schenk et al., 2011; McGinn et al., 2012; Southgate et al., 2010) . In the developing mouse retina, Wnt signaling between rods and RBCs is required for functional synaptic targeting and OPL lamination, and CRISPR-mediated inactivation of Wnt5 resulted in rod/RBC mistargeting and the formation of ectopic OPL (Sarin et al., 2018) . Similarly, Ccl5-mediated chemokine signaling was found to be required for RBC axon terminal targeting to AII amacrine cell dendrites in the IPL (Duncan et al., 2018) , suggesting that both Wnt-and chemokine-dependent mechanisms are active during RBC dendritic and axonal development. No relationship between TPBG and Wnt or chemokine signaling in the retina have yet been shown.
However, as TPBG expression in RBCs increases concurrently with the activation of developmental processes dependent on these signaling pathways, it's possible that TPBG is modulating similar signaling pathways in the retina RBCs.
We found that both antibodies against TPBG label an unidentified population of amacrine cell with a low-density distribution of cell bodies in the INL and dense dendritic stratification between the ON and OFF sublamina in the IPL ( Figure 5 ). This TPBG-positive amacrine cell was first identified in a study focusing on TPBG in mouse olfactory bulb granule cells (Imamura et al., 2006) . Based on similarities in cell body distribution and dendritic lamination density, we hypothesize that this might be the Type 47 (ac53-59) amacrine cell identified via connectomic reconstruction of the IPL, which was shown to receive inputs from cone bipolar cell 5D (XBC) and project outputs to two distinct populations of ganglion cells between the ON and OFF sublamina (Helmstaedter et al., 2013 
